In Science this week: the synthetic genetic system hachimoji, and more.
Emedgene, which makes AI-based, automated genomic interpretation software, will use the Series A funding to expand its US sales operations.
The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
IBM and the Broad Institute will codevelop algorithms to apply artificial intelligence to predict cardiovascular risk from genomic and clinical data.
The Swiss firm's ScaiVision software identifies disease-linked cells using AI, data visualization, and automation of hypothesis testing.
The firm will use the funds to improve market entry and expedite development of its artificial intelligence-based software that analyzes single-cell data.
The company has begun piloting the software, which is targeted towards bioinformatics companies and clinical laboratories, with early adopters ahead of the planned launch.
The Series E financing will go, in part, toward expansion of the company's US presence by growing its workforce and marketing to more American hospitals.
Biocept will offer patient data from its liquid biopsy tests to Prognos, who will apply artificial intelligence to ensure that patients receive correct therapies.
Silicon Valley Startup Jungla has a 10-year vision of its founders to improve large-scale correlation of mutations and disease.
NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.
Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.
In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.